Insights

Analysis of pharmaceutical markets, deals, regulation and manufacturing across MENA, the GCC, Africa, the CIS and Southeast Asia, from Emerging Pharma Tech.

Deal Tracker: every emerging-market pharma deal we track →

• Global Napi Signals Two New Localization Projects as Egypt's Manufacturing Push Accelerates

  Egypt's Global Pharmaceutical Group (GPG) has put down another marker in the country's localization drive — using its first Annual Manufacturing Excellence Forum, "Partners in Success," to announce two upcoming…

• Pharco to Open First Saudi Plant in Madinah by Mid-2027

  Egypt's Pharco is taking its Gulf ambitions from export to manufacturing. One of Egypt's largest drugmakers will open its first Saudi factory in Madinah by mid-2027, investing roughly EGP 2.5 billion (~$49 million)…

• Africa's GLP-1 Signal: What Aspen's Mounjaro Numbers Really Tell MENA

  The $124M target is the headline. The three things underneath it are the story.

• Another Egyptian pharma eyes the EGX: El Arabi Group targets a $100M+ float

  Egyptian drugmaker El Arabi Group (EPG) plans to list a minority stake on the Egyptian Exchange in the third quarter of 2027, aiming to raise more than $100 million to fund a two-year expansion program — potentially…

• GCC digitizes its pharma backbone: inside the Gulf Health Council's Taawon 2.0

  The Gulf Health Council (GHC) — the Riyadh-based body that coordinates health cooperation across the six GCC states — has publicly thanked the pharmaceutical companies that created accounts on Taawon 2.0 and began…

• When Korea Comes to Riyadh: A Biotech Bridge Worth Watching

  RGMBS 2026 · Korean Pavilion Webinar — and what it opens for MENA

• Celltrion advances Keytruda & Darzalex biosimilars

  🔬 Company in focus: Celltrion (068270.KS) — building the next two oncology mega-biosimilars Korea's Celltrion just moved two of the biggest oncology biosimilar opportunities on the planet a step forward. On 7…

• The Out-Licensing Imperative: What Bio-Thera's Balance Sheet Reveals About China's Innovation Exodus

  Bio-Thera Solutions looks like a success story — approved biosimilars, revenue scaled to ~CNY 935M, gross margins near 78%. But look closer at the financials and a different picture emerges: the company has never…

• China Pharma in MENA: The Complete Deal Tracker & Strategic Outlook

  While 42% of China pharma out-licensing targets the US/EU/Japan and 35% seeks global rights, only 14% flows to non-traditional markets — MENA, Southeast Asia, South Korea, and India combined

• The Loss-of-Exclusivity Playbook in Saudi Arabia

  How a $86M diabetes blockbuster defends itself when the patent falls — and which multinationals face the same reckoning next

• Merck is localizing its diabetes blockbusters in Saudi Arabia.

  MSD will manufacture Januvia® and Janumet® at Dammam Pharma — technology transfer, workforce training, supply-chain localization — announced through the Local Content & Government Procurement Authority's Economic…

• MODON ⇄ Aurobindo Pharma

  Saudi Arabia (host) · India (investor) · Greenfield manufacturing / Localization · Human medicines · KSA What was signed. MODON (the Saudi Authority for Industrial Cities and Technology Zones) signed an industrial…

• Mubadala Bio Just Proved the Other Half of Its Thesis

  A local hemodialysis launch looks routine. Read against its Biosidus deal, it reveals a sovereign platform quietly building an end-to-end renal-care franchise.

• Brand Warriors vs. Cost Champions

  When executing a country-specific market entry strategy in the MENA region, your commercial budget is won or lost on the physician's prescription pad. Before spending a single dollar on deployment, you must determine…

• Unlocking the $40B MENA Pharma Opportunity

  The Middle East and North Africa (MENA) pharmaceutical market is undergoing an unprecedented boom. Driven by a growing geriatric population, fluctuating regional economic pressures, and an absolute surge in chronic…

• 𝐌&𝐀 𝐁𝐨𝐨𝐦 𝐨𝐧 𝐭𝐡𝐞 𝐇𝐨𝐫𝐢𝐳𝐨𝐧 𝐟𝐨𝐫 𝐌𝐄𝐍𝐀 𝐏𝐡𝐚𝐫𝐦𝐚

  An annual growth rate exceeding 7–9% and a total valuation crossing $40 billion makes the MENA pharmaceutical market one of the most dynamic expansion landscapes globally. The drive toward geographic consolidation…

• Deep Dive into The "Senior" Distributor

  We have reached the absolute peak of the pharmaceutical distribution landscape. Inside The Powerhouses tier sits the ultimate corporate titan: sub-category F, The "Senior" Distributor. When a brand’s commercial…

• Partner Profiles: Deep Dive into The "Adult" Distributor

  As we conclude our look at The Established Players, we reach sub-category D: The "Adult" Distributor (Type E). If the Child archetype represents tactical, retail-driven integration, the Adult distributor represents…

• Archetypes of Pharma Partnerships: The "Teenager" Local Partner

  In the complex landscape of regional pharmaceutical distribution, selecting the right local partner is critical to long-term market success. Following our analysis of previous partner models, we now explore the fourth…

• Partner Profiles: Deep Dive into The "Child" Distributor

  Moving into our second major tier—The Established Players—we find sub-category C: The Child. Do not let the name fool you. In business terms, a "Child" is an existing, cash-generative market player—typically a strong…

• Partner Profiles: Deep Dive into The "Born Big" Distributor

  The second archetype within The Trailblazers quadrant is sub-category B: The Born Big player. While they share the same youthful age bracket as the Newborns (typically 1 to 3 years old), their operational DNA is…

• Partner Profiles: Deep Dive into The Newborn Distributor

  In our classification matrix, The Trailblazers represent the entry point of market disruption. At the very edge of this category sits sub-category A: The Newborn.

• Partner Profiles: A Spectrum of Expertise in Pharma

  Venturing into new pharmaceutical markets requires a strategic local partner. In our last post, we highlighted how the right distributor eases regulatory burdens, expedites market access, and navigates complex cultural…

• The Silent Killer: The $35,000 Cost of Dead Deals in Principal-Distributor Partnerships

  We have all been there—brand owners and regional distributors alike. You pour weeks of energy into due diligence, align on initial term sheets, map out regional forecasts, and maybe even draft the Exclusive…

• Beyond Revenue & Cost: Building Stronger Relationships with the "Alliance Health Check"

  As channel managers, our default setting is to judge distributor performance by the numbers. We look at sales velocity, inventory turnover, margin optimization, and cost efficiency. While maximizing revenue is crucial…

• M&A in MENA Pharma: Perspective on a Shifting Landscape

  The Middle East and North Africa (MENA) pharmaceutical industry is undergoing a quiet but powerful transformation. As a student analyzing Merger & Acquisition (M&A) frameworks at Imperial Business School, and a close…

• Beyond the Logistics: The 7 Mindsets of a Master Distributor Manager

  When expansion plans across a region fail, companies often look straight at the technicalities. They blame supply chain bottlenecks, regulatory hiccups, or misaligned pricing models. But if you look closer, the failure…

• The Export Manager’s Essential Toolkit: 23 Key Terms and Documents for Global Success

  Working with distributors across different countries means navigating various languages and cultures. Fortunately, international trade relies on a universal language of business expressions and standard documentation.

• Revitalizing Underperforming Markets: 8 Action Steps for Export Managers

  Every exporter faces countries where brand performance falls short of expectations—especially painful when it's a strategic market like Saudi Arabia or Egypt.

• Optimizing Retail Pricing: Beyond the Fixed Equation

  We've observed many consumers and distribution partners relying on a fixed formula to set retail prices. This one-size-fits-all approach often leads to critical pricing errors—either overpricing and losing market…

• 5 Strategies to Find the Right Pharma Distributor
• Proactive Distributor Selection: Choose Them, Don't Let Them Choose You

  When I started as an export manager, I was overwhelmed by the basics: Which country? Which products? How to price? If you feel the same, you aren't alone.

• Bridging the Gap: Essential Information for Pharma Distributors

  A common friction point between export managers and company owners is information sharing. Owners often hesitate to reveal costs, sales strategies, and marketing plans, which frequently leads to disputes over pricing…

• Recordati's €2.3B Secret: Why MENA Pharma Is Playing the Wrong Game

  From a €192 million domestic Italian player in 1997 to a €2.3 billion global specialty leader in 2024, Recordati’s 25-year journey is a masterclass in pharmaceutical scaling. From €192M to €2.3B in 25 years. While most…

• The Great GCC Pharma Power Shift: Why Your 2010 Strategy Is Killing Your 2026 Results

  We've seen it all in GCC pharma over the last 20 years. But here's the uncomfortable truth: while the market has evolved through four distinct eras, too many companies are still playing by pre-2010 rules.

• The GCC Generics Clock: Why You Have Only 5-8 Years to Win

  In GCC generics markets, time is your harshest competitor. Our analysis of 2,100 pricing records spanning 15+ years reveals an uncomfortable truth: the window for profitable generic entry closes faster than most…